AMLX - Amylyx Pharmaceuticals, Inc.
17.59
0.020 0.114%
Share volume: 814,579
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.15%
PREVIOUS CLOSE
CHG
CHG%
$17.57
0.02
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-08-2024 | 11-07-2024 | 03-04-2025 | 05-08-2025 | 11-06-2025 | 03-03-2026 | |
| Assets | ||||||||
| Total Assets | 417.457 M | 332.162 M | 250.713 M | 193.634 M | 219.676 M | 362.741 M | 332.645 M | |
| Current Assets | 410.534 M | 326.722 M | 245.263 M | 189.432 M | 216.144 M | 353.383 M | 323.671 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 202.741 M | 234.813 M | 162.556 M | 99.110 M | 144.304 M | 118.812 M | 90.328 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 170.552 M | 74.999 M | 71.839 M | 77.391 M | 59.764 M | 225.178 M | 226.651 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 2.459 M | 1.473 M | 1.252 M | 961.000 K | 816.000 K | 399.000 K | 310.000 K | |
| Other Assets | 4.464 M | 3.967 M | 4.198 M | 3.241 M | 2.716 M | 8.959 M | 6.166 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 417.457 M | 332.162 M | 250.713 M | 193.634 M | 219.676 M | 362.741 M | 332.645 M | |
| Total liabilities | 93.021 M | 70.853 M | 54.510 M | 28.869 M | 18.259 M | 30.745 M | 27.386 M | |
| Total current liabilities | 91.639 M | 70.081 M | 53.915 M | 28.406 M | 17.932 M | 25.791 M | 22.688 M | |
| Accounts Payable | 21.453 M | 4.955 M | 1.487 M | 2.939 M | 4.810 M | 5.339 M | 3.519 M | |
| Other liabilities | 1.382 M | 772.000 K | 595.000 K | 463.000 K | 327.000 K | 4.954 M | 4.698 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 1.382 M | 772.000 K | 595.000 K | 463.000 K | 327.000 K | 4.954 M | 4.698 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 324.436 M | 261.309 M | 196.203 M | 164.765 M | 201.417 M | 331.996 M | 305.259 M | |
| Common stock | 748.255 M | 757.848 M | 764.708 M | 771.549 M | 844.016 M | 1.050 B | 1.056 B | |
| Retained earnings | -423.742 M | -496.442 M | -569.146 M | -606.692 M | -642.599 M | -718.428 M | -751.427 M |